S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:ADAP

Adaptimmune Therapeutics - ADAP News Today

$1.10
+0.01 (+0.92%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.06
▼
$1.12
50-Day Range
$1.09
▼
$1.87
52-Week Range
$1.01
▼
$2.65
Volume
562,736 shs
Average Volume
1.02 million shs
Market Capitalization
$170.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
Get Adaptimmune Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.


ADAP Media Mentions By Week

ADAP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADAP
News Sentiment
▼
0.58

0.67
▲
Average
Medical
News Sentiment

ADAP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADAP Articles
This Week
▼
5

2
▲
ADAP Articles
Average Week

SourceHeadline
marketbeat.com logoAdaptimmune Therapeutics plc (NASDAQ:ADAP) Receives Consensus Rating of "Moderate Buy" from Analysts
marketbeat.com - March 24 at 10:25 AM
MarketBeat logoAdaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at Bryan, Garnier & Co
americanbankingnews.com - March 25 at 5:48 AM
marketwatch.com logoSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of TCR2 Therapeutics Inc. (TCRR)
marketwatch.com - March 24 at 7:45 AM
MarketBeat logoAdaptimmune Therapeutics (NASDAQ:ADAP) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - March 16 at 5:06 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Foghorn Therapeutics (FHTX) and Rain Therapeutics (RAIN)
markets.businessinsider.com - March 10 at 3:15 PM
finance.yahoo.com logoNews Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
finance.yahoo.com - March 8 at 10:20 AM
finance.yahoo.com logoAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript
finance.yahoo.com - March 8 at 10:20 AM
marketwatch.com logoTCR Therapeutics Shares Rise, Adaptimmune ADS's Slide on Tie-Up
marketwatch.com - March 6 at 5:37 PM
markets.businessinsider.com logoAnalysts Are Bullish on Top Healthcare Stocks: CTI BioPharma (CTIC), Adaptimmune Therapeutics (ADAP)
markets.businessinsider.com - March 6 at 5:37 PM
bizjournals.com logoAdaptimmune to acquire Boston-area cell therapy company TCR² Therapeutics
bizjournals.com - March 6 at 5:37 PM
finance.yahoo.com logoAdaptimmune Agrees To Merge With Another Cell Therapy Focused Company
finance.yahoo.com - March 6 at 5:37 PM
marketwatch.com logoAdaptimmune to Buy TCR Therapeutics in $103M Stock Swap >ADAP TRCC
marketwatch.com - March 6 at 10:01 AM
msn.com logoAdaptimmune Craters after Acquiring TCR² Therapeutics
msn.com - March 6 at 10:01 AM
finance.yahoo.com logoAdaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
finance.yahoo.com - March 6 at 10:01 AM
marketwatch.com logoNeuroblastoma Treatment Industry (Views and Position) 2023-2028
marketwatch.com - March 6 at 5:01 AM
msn.com logoAdaptimmune Therapeutics's Earnings Outlook
msn.com - March 3 at 6:35 PM
marketwatch.com logoTCR-Based Antibody Market 2023: Growth by 2029 Top Players with Opportunities
marketwatch.com - February 28 at 8:34 AM
benzinga.com logoAdaptimmune Therapeutics Stock (NASDAQ:ADAP), Quotes and News Summary
benzinga.com - February 26 at 11:15 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Infinity Pharma (INFI) and Leap Therapeutics (LPTX)
markets.businessinsider.com - February 23 at 5:19 PM
markets.businessinsider.com logoAnalysts Are Bullish on These Healthcare Stocks: Biora Therapeutics (BIOR), IN8bio (INAB)
markets.businessinsider.com - February 23 at 5:19 PM
finance.yahoo.com logoAdaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
finance.yahoo.com - February 22 at 12:52 PM
finance.yahoo.com logoAdaptimmune Announces Changes to Board of Directors
finance.yahoo.com - February 16 at 9:18 AM
marketwatch.com logoAn Overview of Neuroblastoma Treatment Market, Major Participants, and Prospects by 2028
marketwatch.com - January 18 at 2:04 PM
finance.yahoo.com logoPublication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
finance.yahoo.com - January 9 at 10:23 AM
finance.yahoo.com logoEven after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five years
finance.yahoo.com - January 8 at 12:21 PM
benzinga.com logoPneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors
benzinga.com - January 6 at 8:48 AM
markets.businessinsider.com logoExpert Ratings for Adaptimmune Therapeutics
markets.businessinsider.com - January 5 at 2:28 PM
markets.businessinsider.com logoVerismo Therapeutics Expands Quality and Compliance Team
markets.businessinsider.com - January 3 at 2:05 PM
finance.yahoo.com logo3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
finance.yahoo.com - December 27 at 2:52 PM
finance.yahoo.com logoAdaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
finance.yahoo.com - December 23 at 2:05 PM
finance.yahoo.com logoHedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year losses
finance.yahoo.com - December 10 at 5:10 PM
finance.yahoo.com logoData from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
finance.yahoo.com - November 18 at 8:13 AM
markets.businessinsider.com logoSVB Securities Reaffirms Their Hold Rating on ImmunoGen (IMGN)
markets.businessinsider.com - November 16 at 2:22 PM
finance.yahoo.com logoReCode Therapeutics Establishes Scientific Advisory Board
finance.yahoo.com - November 14 at 8:19 AM
finance.yahoo.com logoNew Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
finance.yahoo.com - November 13 at 5:01 PM
finance.yahoo.com logoLab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing
finance.yahoo.com - November 11 at 2:34 PM
bizjournals.com logoVeterans of Influence Awards 2022: John Lunger, Adaptimmune Therapeutics
bizjournals.com - November 10 at 6:32 PM
finance.yahoo.com logoAdaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations
finance.yahoo.com - November 10 at 6:32 PM
finance.yahoo.com logoAdaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business
finance.yahoo.com - November 8 at 5:56 PM
finance.yahoo.com logoWhy Adaptimmune Therapeutics Stock Is Glowing Green Today
finance.yahoo.com - November 8 at 5:56 PM
finance.yahoo.com logoAdaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
finance.yahoo.com - November 8 at 9:33 AM
finance.yahoo.com logoAdaptimmune Reports Third-Quarter Financial Results and Business Update
finance.yahoo.com - November 8 at 9:33 AM
finance.yahoo.com logoAdaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
finance.yahoo.com - October 27 at 5:35 PM
finance.yahoo.com logoAdaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
finance.yahoo.com - October 25 at 11:15 AM
marketwatch.com logoT-Cell Immunotherapy Market Insights : Industry dynamics, New Technologies and Forecast to 2027
marketwatch.com - September 29 at 2:34 PM
markets.businessinsider.com logoMizuho Securities Reaffirms Their Hold Rating on Incyte (INCY)
markets.businessinsider.com - September 27 at 7:27 AM
nasdaq.com logoAfter a 24% dip, insiders are undoubtedly glad they sold Adaptimmune Therapeutics plc (NASDAQ:ADAP)
nasdaq.com - September 26 at 7:19 PM
seekingalpha.com logoAdaptimmune Therapeutics: Depressed Despite Upcoming BLA
seekingalpha.com - September 20 at 12:33 PM
seekingalpha.com logoAdaptimmune Therapeutics (ADAP) Presents At ESMO Congress 2022 - Slideshow
seekingalpha.com - September 16 at 7:32 PM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adaptimmune Therapeutics plc - ADAP
benzinga.com - September 12 at 6:08 PM
morningstar.com logoADRs End Higher, Argo Blockchain and Adaptimmune Therapeutics Trade Actively
morningstar.com - September 10 at 9:08 PM
Get Adaptimmune Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ADAP) was last updated on 3/25/2023 by MarketBeat.com Staff